Lumos Pharma Inc Overview
Industry: Biotechnology
Sector: Healthcare
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Lumos Pharma Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Lumos Pharma Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Lumos Pharma Inc Competitors
Lumos Pharma Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans